Xarelto: Can it compete with Eliquis

Who thinks Xarelto's data is going to be able to compete with Eliquis?

 

Going to get smoked

 

Agreed, especially if our training is saying that our messaging is just as good as coumadin

 

When is apixaban supposed to come out?

 

Supposed to be next year.

 

Have we received any updates on approval?

 

Now that I have seen the data for Xarelto, I can say that we are definitely screwed!

 

Eliquis will not get ACS. Also, their stroke data is strong, but with bid dosing. You can pretty much get people to adhere to bid dosing in a clinical trial setting, but in the real world? Assuming a lower compliance rate in the real world for bid dosing, can you really rely on better real world outcomes vs a qd product?

 

---------------------

warfarin is qd.
failed warfarin is better then rivaroxaban.
bid or qd doesn't matter in this market.
what matters is morbidity and mortality.
riva is a dog, which is why peole from jansen are leaving in waves.

 

Oh really? People leaving. In this economy. Right,

 

Probably shouldn't respond to your incoherent attempt at putting us down but...

http://www.bloomberg.com/news/2011-11-13/pfizer-bristol-drug-doesn-t-cut-leg-clots-after-hospital-stay.html

Apixaban is not the slam dunk you think it is.

 

You ate an idiot if you don't think apixaban is going to destroy Xarelto

 

What whacky weed are you smoking???

If a patient misses a BID dose they pick back up in 12 hrs. IF a patient misses your QD dose they don't pick it back up for 24 hours. When you are talking about acid reflux then who cares, but since it's stroke risk reduction you want to be as quickly covered as possible.


Don't get me started on zarelto's 6 hr half-life that supposed to cover you for 24 hrs????? This is a big time danger waiting to happen, good luck trying to spin this.

 

No, but between Pradaxa and Apixaban I'm sure your "equivalent warfarin replacement" called zarelto will get some play. Just bottom of the rotation after the A-rods get a go at bat.

 

Here's the TRUTH
http://www.theheart.org/article/1268723.do

 

However, RE-LY investigator Dr Salim Yusuf (McMaster University, Hamilton, ON) pointed out to heartwire that although the ARISTOTLE results were very good, apixaban did not show a reduction in ischemic stroke, whereas the 150-mg dabigatran dose in RE-LY did. He said he would position the ARISTOTLE result "somewhere in between the two doses of dabigatran in RE-LY."

Ouch for apixaban since 85% of ALL strokes are ischemic strokes; to not provide any protection from this seems a P-dax will get you covered. Thanks for the link, bra.

 

Based on the response thus far, it looks like we are in trouble

 

Apixiban has a chance to get a total mortality indication, if so - game over.

 

Xarelto - Can Eliquis compete with Xarelto?

Xarelto soon to have three indications. Pradaxa has one...Eliquis currently has zero!

Check back on this thread in 2013 only then can you declare a winner by looking at the market share. At the end of the day more new anticoagulants hitting the market will benefit all four companies. Warfarin will start to fade away with four companies sharing the benefits of the new products.
Warfarin is the is the number one anticoagulant today, once it is below 30% you can claim bragging rights about your drug, but not until then!
Have a good life and enjoy the ride, you have a damn good job!

 

2 months of data, and only 5 scripts of Xarelto in our territory.

(All from the 2 speakers)

I am not joking. I expected there to be some interest in a once a day new anti-coag, but the only feedback has been that the drug, the trial and the company are useless.

Continued focus on Warfarin, plan for Eliquis, keep speakers and top offices happy.